LINC01220: LINC01220 is a long non-coding RNA (lncRNA) that has been shown to play a role in endometrial carcinoma (EC) [PMC9100904]. Knockdown of LINC01220 in EC has been found to inhibit proliferation and induce apoptosis, suggesting its potential as a therapeutic target [PMC9100904]. LINC01220, along with several other lncRNAs, is upregulated in EC cells compared to normal cells [PMC9100904]. These upregulated lncRNAs are associated with various pathways involved in androgen response, apoptosis, DNA repair, IL2-STAT5 signaling, MTORC1 signaling, oxidative phosphorylation, and TNFA-signaling via NFKB pathways [PMC9100904]. LINC01220 expression is significantly upregulated in EC tissues and is strongly associated with tumor stage [PMC7532893][PMC6658720]. Silencing LINC01220 has been shown to suppress proliferation and promote apoptosis of EC cells [PMC7532893][PMC6658720]. Additionally, LINC01220 expression is positively correlated with pathological grade and FIGO staging of EC patients [PMC6658720]. Furthermore, LINC01220 has been found to regulate MAPK11 expression in EC cells [PMC6658720]. Knockdown of LINC01220 decreases MAPK11 protein levels and inhibits colony formation ability of EC cells [PMC6658720]. Overall, these findings suggest that LINC01220 may serve as a potential diagnostic marker for EC and may play a role in promoting the progression of the disease through its effects on proliferation and apoptosis via MAPK11 regulation [PMC7532893][PMC6658720]. However, further research is needed to fully understand the mechanisms by which LINC01220 functions in EC cells and its potential as a therapeutic target for the disease.